

What Clinicians Want To Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the VIALE-A study, patients with newly diagnosed acute myeloid leukemia (AML) and which of the following molecular markers experienced improved response and survival with venetoclax/azacitidine in comparison to patients with other markers?

 - a. FLT3
 - b. IDH1/2**
 - c. TP53
 - d. NPM1
2. Which of the following outcomes was observed in the QUAZAR AML-001 trial investigating the efficacy of CC-486 (oral azacitidine) as maintenance therapy for patients with AML in first remission after induction chemotherapy?

 - a. Statistically significant improvement in only overall survival (OS) with CC-486
 - b. Statistically significant improvement in only relapse-free survival (RFS) with CC-486
 - c. Statistically significant improvement in RFS and OS with CC-486**
 - d. None of the above
3. Which of the following overall response rates was observed with ivosidenib for patients with relapsed/refractory AML with IDH1 mutations?

 - a. ~20%
 - b. ~30%
 - c. ~40%
 - d. ~50%**
4. Which of the following Grade 3 to 5 adverse events is most commonly associated with CPX-351 among older patients with newly diagnosed secondary AML?

 - a. Febrile neutropenia**
 - b. Sepsis
 - c. Respiratory failure
 - d. Hypoxia